Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.

ABSTRACT:

Objective

We evaluated the activity and safety of the combination of topotecan, cisplatin and bevacizumab in patients with recurrent or persistent carcinoma of the cervix.

Methods

Eligible patients had persistent or recurrent cervical cancer not amenable to curative intent treatment. No prior chemotherapy for recurrence was allowed. Treatment consisted of cisplatin 50 mg/m(2) day 1, topotecan 0.75 mg/m(2) days 1, 2 and 3 and bevacizumab 15 mg/kgday 1 every 21 days until disease progression or limiting toxicity. The primary endpoint was progression free survival at 6 months. We explored PET/CT as a potential early indicator of response to therapy.

Results

Twenty-seven eligible patients received a median of 3 treatment cycles (range, 1-19). Median follow-up was 10 month

SUBMITTER: Zighelboim I 

PROVIDER: S-EPMC3870479 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature